COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY FOR TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM

Michele Wilson  1     Matthew Kerrigan  2     Michael Smyth  3     Helene Chevrou-Severac  4     Annika Bergman  4     Ross Selby  5    
1 RTI Health Solutions,Research Triangle Park,United States
2 PHMR Limited,London,United Kingdom
3 Takeda Development Centre Europe Ltd.,London,United Kingdom
4 Takeda Pharmaceuticals GmbH,Zurich,Switzerland
5 Takeda UK Ltd.,Bucks,United Kingdom

Conference
UEG Week 2015

Citation
United European Gastroenterology Journal; 2015: 2 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing